Key Drivers
- Strong liquidity
- Quarterly cash drain
- High valuation
AIAI Summary
The Cullgen acquisition and near‑term China regulatory catalysts recast Gyre as a hybrid commercial + R&D story—providing upside if Hydronidone gains conditional approval and TPD assets show early promise, but turning materially negative if integration, regulatory sequencing, or cash‑flow strain force dilution given the stock already prices aggressive growth. Monitor Hydronidone conditional approval/reimbursement progress and a smooth Cullgen close plus early TPD data as the specific binary catalysts that will validate or break the current valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Quarterly cash drain
- •High valuation
GYRE combines strong liquidity, negligible debt and very high gross margins with modest annual profits but acute quarterly cash‑flow losses, deep accumulated deficits and stretched valuation that raise downside risk if near‑term performance worsens.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Recent low hold
- •Strong resistance
GYRE is in a clear short-term downtrend (last month) after a decisive ~18.7% fall from $8.28 to $6.72, trading below the $7.92 SMA and facing resistance at $8.76 until it can reclaim the moving average.
Sharp ~18.7% decline since 2026-02-20 signaling bearish momentum
Sentiment & News
Key News Insights:
- •Revenue +10%
- •EPS miss
- •Regulatory priority
Gyre posted 2025 revenue up 10% but an EPS miss and narrower 2026 guidance while advancing a Cullgen acquisition, winning NMPA priority review for Hydronidone, and completing Phase 3 enrollment.
The combination of commercial growth, M&A and China regulatory wins should support upside sentiment, but the EPS miss and tighter guidance leave near-term stock volatility elevated
Similar Companies in Healthcare
Other companies in the same sector with AI ratings